Treatment for Prostate Cancer: Stage 3, Stage 4, High Risk & Metastatic Options

Prostate cancer treatment has changed dramatically in the past decade. Drugs like enzalutamide (Xtandi), abiraterone (Zytiga/Yonsa), and the PSMA-targeted radioligand therapy lutetium-177 vipivotide tetraxetan (Pluvicto) have extended survival for men with advanced and metastatic disease.

This guide covers the latest treatments and emerging therapies — from surgery and radiation to hormonal agents, targeted drugs, and PSMA-directed therapies — with a focus on the treatment decisions that matter most to men with high-risk or advanced disease.

1. How Risk Group Shapes Your Treatment Path

After diagnosis, your oncology team classifies disease by risk group — a combination of PSA level, Gleason/Grade Group score, and clinical stage. Risk group is the primary driver of which treatment is recommended:

• Low risk: Active surveillance is often appropriate — no immediate treatment needed.
• Intermediate risk: Surgery (radical prostatectomy) or radiation therapy (IMRT/SBRT) are the primary options.
• High risk / locally advanced: Combined modality approaches — typically radiation plus long-term androgen deprivation therapy (ADT), often with a next-generation hormonal agent.
• Metastatic / stage 4: Systemic therapy is central — ADT combined with agents such as enzalutamide (Xtandi), abiraterone (Zytiga), apalutamide (Erleada), darolutamide (Nubeqa), docetaxel, PARP inhibitors, and PSMA-targeted therapy (Pluvicto) depending on stage and prior treatment.

2. Best Treatment for High Risk & Locally Advanced Prostate Cancer

High-risk prostate cancer is defined by any one of: PSA above 20 ng/mL, Gleason Grade Group 4–5, or clinical stage T3. Locally advanced prostate cancer — disease that has grown beyond the prostate capsule but has not yet spread to distant organs — falls in this category. These cases typically require aggressive, often combination, treatment.

Radiation plus long-term ADT

For most men with high-risk or locally advanced prostate cancer, external beam radiation therapy (EBRT) combined with 18–36 months of androgen deprivation therapy (ADT) is the established standard of care. The addition of a next-generation hormonal agent has been shown to strengthen outcomes in this setting.

The STAMPEDE platform trial demonstrated that adding abiraterone acetate plus prednisolone to ADT significantly improved metastasis-free survival (HR 0.53) and overall survival (HR 0.60) in men with high-risk nonmetastatic prostate cancer.^[1]

Surgery for locally advanced prostate cancer

Radical prostatectomy is an option for selected men with locally advanced (T3a) disease at high-volume, experienced surgical centers. It provides definitive pathological staging and allows adjuvant radiation if surgical margins are positive. Extended pelvic lymph node dissection is standard for this stage. Surgery alone is rarely sufficient — most men with high-risk features will need adjuvant or salvage radiation.

3. Best Treatment for Prostate Cancer Stage 3

Stage 3 prostate cancer is divided into 3A (PSA ≥20 or Grade Group 4–5, organ-confined), 3B (tumor extends beyond the capsule or into seminal vesicles), and 3C (Grade Group 5, any PSA). Stages 3B and 3C correspond to the high-risk and locally advanced categories.

Treatment for prostate cancer stage 3 typically involves:

• External beam radiation (IMRT or SBRT) to the prostate and pelvic lymph nodes, combined with 18–36 months of ADT.
• The addition of abiraterone (Zytiga/Yonsa), based on STAMPEDE data, for men with high-risk features.^[1]
• Next-generation hormonal options including apalutamide (Erleada) and darolutamide (Nubeqa) are approved for nonmetastatic castration-resistant disease and are being studied in the hormone-sensitive high-risk setting.
• Radical prostatectomy with extended lymph node dissection at experienced centers — followed by adjuvant therapy based on pathology.
• Clinical trial enrollment — several trials are actively studying treatment intensification for stage 3 disease. Search enrolling studies at ClinicalTrials.gov.

4. Best Treatment for Prostate Cancer Stage 4

Stage 4 prostate cancer encompasses two situations: stage 4A (cancer in regional lymph nodes) and stage 4B — metastatic prostate cancer that has spread to bones, distant lymph nodes, or other organs. Treatment goals and drug selection differ significantly.

Stage 4A: Regional lymph node involvement

Men with stage 4A disease are often treated with curative intent. Radiation to the prostate and pelvis plus long-term ADT is the primary approach. Adding abiraterone (Zytiga) has shown improved outcomes in node-positive patients in the STAMPEDE trial.^[1] Surgery is an option at experienced centers. At minimum, medication for prostate cancer stage 4A should include ADT plus abiraterone or another approved next-generation hormonal agent.

Stage 4B: Metastatic prostate cancer — first-line treatment

Metastatic prostate cancer — cancer that has spread beyond the pelvis — is managed as a systemic disease. The standard approach now combines ADT with at least one additional agent from the outset:

• ADT plus abiraterone (Zytiga/Yonsa): The LATITUDE trial (published in The Lancet Oncology) showed that ADT plus abiraterone and prednisone reduced the risk of death by 38% versus ADT alone in men with newly diagnosed high-risk metastatic prostate cancer (HR 0.62; P<0.0001). STAMPEDE confirmed these findings.^[3]
• ADT plus enzalutamide (Xtandi): The ARCHES and ENZAMET trials established enzalutamide as an effective alternative to abiraterone in metastatic castration-sensitive prostate cancer (mCSPC).^[4]
• ADT plus apalutamide (Erleada): The TITAN trial demonstrated improved overall survival with apalutamide plus ADT versus ADT alone.^[5]
• ADT plus darolutamide (Nubeqa): Approved for nonmetastatic castration-resistant prostate cancer based on the ARAMIS trial, and studied in combination with docetaxel in the mHSPC setting (ARASENS trial).^[6]
• Docetaxel (Taxotere) for high-volume disease: The CHAARTED trial showed that adding 6 cycles of docetaxel to ADT significantly extended overall survival in men with high-volume metastatic disease (57.6 months vs 44 months; HR 0.61), but no survival benefit was observed for low-volume disease.^[7] High-volume disease is defined as visceral metastases and/or ≥4 bone metastases.
• Bone-targeted agents: Zoledronic acid or denosumab to reduce skeletal complications in men with bone metastases.

5. Treatment for Metastatic Prostate Cancer After Hormone Therapy Stops Working (mCRPC)

When prostate cancer continues to grow despite castrate levels of testosterone, it is classified as metastatic castration-resistant prostate cancer (mCRPC). The best treatment for prostate cancer that has spread and become castration-resistant involves several drug classes:

Next-generation hormonal agents in mCRPC

Enzalutamide (Xtandi) and abiraterone (Zytiga) remain foundational in mCRPC. The PREVAIL trial showed enzalutamide reduced the risk of death by 17% versus placebo (HR 0.83; P<0.001) in chemotherapy-naive mCRPC, with median overall survival of 35.5 months versus 31.4 months.^[9] COU-AA-302 demonstrated similar overall survival benefit for abiraterone (Zytiga) in this population.

On the question of sequencing: using abiraterone following enzalutamide (and vice versa) shows reduced activity due to overlapping mechanisms. When one agent has been used and disease has progressed, the same class is unlikely to offer significant benefit. Enrollment in a clinical trial at this point is strongly recommended.

Pluvicto: PSMA-targeted radioligand therapy

Lutetium-177 vipivotide tetraxetan (Pluvicto) was FDA-approved on March 23, 2022, based on the pivotal Phase III VISION trial. In VISION, men with PSMA-positive mCRPC who had received prior ADT and taxane-based chemotherapy and who received Pluvicto plus standard of care had a 38% reduction in risk of death (HR 0.62) compared to standard of care alone (median OS: 15.3 vs 11.3 months).^[10]

PARP inhibitors for DNA repair gene mutations

Men with mCRPC whose tumors carry mutations in DNA repair genes (BRCA1, BRCA2, ATM, CDK12) may benefit from PARP inhibitors. Olaparib (Lynparza) and rucaparib (Rubraca) are FDA-approved for BRCA-mutant mCRPC after prior hormonal therapy. Niraparib combined with abiraterone (Akeega) was approved in 2023 for BRCA1/2-mutant mCRPC as a first-line combination option.

Germline genetic testing is now recommended for all men with metastatic prostate cancer — not just those with family history — because actionable mutations are found in approximately 10–15% of men.^[11]

Cabazitaxel and immunotherapy

Cabazitaxel (Jevtana) is second-line chemotherapy for mCRPC after docetaxel, with proven overall survival benefit from the TROPIC trial. Sipuleucel-T (Provenge) is an immunotherapy approved for asymptomatic or minimally symptomatic mCRPC. Pembrolizumab (Keytruda) is approved for mismatch repair-deficient or MSI-high tumors, which represent a small but important subset. Testing for MSI-H/dMMR status is recommended at progression.

6. Newest Treatment for Prostate Cancer and Emerging Therapies (2025–2026)

• Pluvicto in earlier lines (PSMAfore trial): The PSMAfore trial evaluated Pluvicto versus a change of androgen receptor pathway inhibitor in taxane-naive mCRPC and showed significant improvement in radiographic progression-free survival. This data supported an FDA label expansion of Pluvicto to patients who have not yet received chemotherapy, for eligible patients. The label was expanded in 2024.
• Akeega (niraparib + abiraterone): FDA-approved 2023 for BRCA1/2-mutant mCRPC — the first combination PARP/hormonal agent tablet, based on the MAGNITUDE trial.
• Orgovyx (relugolix): An oral GnRH antagonist providing faster testosterone suppression and faster testosterone recovery after stopping versus LHRH agonists (leuprolide, goserelin). The HERO trial showed Orgovyx also had a significantly lower rate of major adverse cardiovascular events, making it the preferred ADT backbone for men with prior cardiac history.^[12]
• Bispecific antibodies and CAR-T: Early-phase trials targeting PSMA, STEAP1, and DLL3 in heavily pre-treated mCRPC are showing initial signals. These are investigational but represent the next wave after radioligand therapy.
• AR degraders (PROTACs): Bavdegalutamide (ARV-110), a PROTAC-class androgen receptor degrader, is in phase 2 trials, designed to overcome resistance mutations that limit enzalutamide and abiraterone.
• Focal therapy (focal laser ablation): Cryotherapy, HIFU, and focal laser ablation are being evaluated for low-to-intermediate risk, organ-confined disease as alternatives to whole-gland treatment. These remain investigational outside specialist centers for most patients and are not recommended for high-risk or advanced disease.

7. Stage 4 Prostate Cancer Survival, Remission & Long-Term Outcomes

Stage 4 prostate cancer is not a uniform prognosis. Men with stage 4A disease treated aggressively with radiation plus intensified systemic therapy now achieve 5-year survival rates above 70% at major cancer centers. Stage 4B (metastatic) 5-year survival is approximately 32% by SEER population data, but this population-level figure substantially understates outcomes for men treated with current intensified regimens.

For context: the LATITUDE and TITAN trials both showed 5-year overall survival of approximately 60–65% in men receiving intensified first-line therapy (ADT plus abiraterone or apalutamide), compared to historical medians of ~42 months with ADT alone.^[3],[5]

Complete remission in metastatic prostate cancer — undetectable PSA with resolution of imaging findings — is achievable in a meaningful minority of men, particularly those with oligometastatic disease treated with metastasis-directed therapy combined with intensified systemic treatment. For men asking whether stage 4 prostate cancer remission is possible: the honest answer is yes for a subset, and significantly prolonged disease control is achievable for many more with current treatments.

Prognosis also varies by metastatic burden and site. Bone-only metastases tend to have better outcomes than visceral (lung, liver) metastases. A low metastatic burden — fewer than 4 bone lesions, no visceral disease — is a favorable prognostic marker. Your medical oncologist can use the CHAARTED high-volume definition or the LATITUDE high-risk criteria to characterize your risk.

8. Recognizing Symptoms of Prostate Cancer and When to Act

While this guide focuses on treatment decisions, symptoms can prompt diagnosis — particularly for advanced disease that has spread before detection. Symptoms that warrant prompt urological evaluation include:

• Urinary changes: difficulty starting, weak stream, frequent nighttime urination, blood in urine.
• Bone pain — particularly in the spine, hips, or pelvis — which can signal prostate cancer that has spread to bone.
• Unexplained weight loss, new leg weakness or numbness (possible spinal cord compression from bone metastases), or new lymph node swelling.
• Elevated PSA found on routine blood work — even without symptoms, a PSA above 20 ng/mL warrants prompt specialist evaluation.

For PSA screening recommendations by age, the USPSTF prostate cancer screening recommendation and the American Cancer Society overview provide age-stratified guidance. Men with a family history of prostate cancer or a BRCA2 mutation should begin screening discussions at age 40–45.

9. Managing Side Effects of Prostate Cancer Treatment

Side effects are highly drug- and regimen-specific. For men on long-term ADT with next-generation hormonal agents:

• Bone health: ADT accelerates bone density loss. Zoledronic acid or denosumab reduces fracture risk. Weight-bearing exercise and calcium/vitamin D supplementation are also standard.
• Cardiovascular risk: Orgovyx (relugolix) has a lower cardiovascular risk profile than LHRH agonists — relevant for men with prior cardiac history, based on the HERO trial cardiovascular substudy.^[12]
• Fatigue: Structured exercise programs designed for men on ADT reduce fatigue and preserve lean mass. Ask for an oncology-certified physical therapist referral.
• Urinary incontinence after surgery: Pelvic floor rehabilitation with a specialist is the most effective early intervention. Most men see significant improvement within 6–12 months.
• Erectile dysfunction: Penile rehabilitation starting early after prostatectomy or radiation — PDE5 inhibitors, vacuum erection devices, or low-intensity shockwave therapy — improves long-term recovery rates. See the American Cancer Society guide to sexual health after cancer.

10. Finding the Best Hospitals and Specialists for Prostate Cancer Treatment

For high-risk, locally advanced, or metastatic disease, treatment at an NCI-Designated Cancer Center or a high-volume institution is strongly associated with better outcomes — particularly for surgical volume, access to PSMA PET imaging, and PSMA-targeted therapy (Pluvicto), which requires specialized nuclear medicine infrastructure.

For advanced prostate cancer, seek a medical oncologist with a dedicated genitourinary oncology focus. Use the NCI Cancer Center finder or ask your urologist for a referral to a GU medical oncologist. A dedicated patient navigator — available through the American Cancer Society — can help with scheduling, insurance navigation, and support.

For coverage of prostate cancer treatment under Medicare — including Part D coverage of enzalutamide (Xtandi) and abiraterone (Zytiga), infusion coverage for Pluvicto under Part B, and radiation benefits — review Medicare's cancer treatment coverage page. Many manufacturers offer patient assistance programs: Astellas provides Xtandi assistance; Janssen provides Zytiga/Yonsa assistance; Novartis provides a Pluvicto patient access program. Ask your oncology nurse navigator for referrals to these programs and to CancerCare financial assistance.